Centre Hospitalier Universitaire de Bordeaux, Place Amélie Raba Léon, 33000 Bordeaux, France.
Centre Hospitalier Universitaire de Bordeaux, Place Amélie Raba Léon, 33000 Bordeaux, France.
Arch Pediatr. 2021 Nov;28(8):621-625. doi: 10.1016/j.arcped.2021.10.004. Epub 2021 Oct 20.
Carbapenems, last-resort antibiotics, are widely used as first-line treatment in patients carrying extended-spectrum beta-lactamases (ESBL) Enterobacteriaceae, including in a pediatric setting. We aimed to implement an antibiotic stewardship program (ASP) to improve the use of carbapenems.
We implemented an ASP at the Bordeaux Children's University Hospital with 6-month audits on prescribing practice before and after an intervention (revision of antibiotic treatment protocols, a half-day educational session with feedback of the first study period). The number of carbapenem prescriptions was analyzed and two criteria were used to assess conformity of the indication for carbapenem prescription and conformity of the reassessment. A logistic regression was used to assess the overall compliance of carbapenem prescriptions over the two periods adjusted for ESBL carriage.
A total of 57 patients were included with 37 carbapenem prescriptions before the intervention and 23 after. Overall carbapenem consumption decreased from 0.54 prescriptions per 100 admissions to 0.32 (p = 0.06). Conformity increased during the study for indication (46-87%, p = 0.004) and for reassessment (48-78%, p = 0.04) and was significantly associated with the second study period, after adjustment for ESBL carriage.
Our intervention contributed to a significant improvement in the compliance to indications for carbapenem indication and in the reassessment of the prescription.
碳青霉烯类抗生素是一种广泛应用于携带超广谱β-内酰胺酶(ESBL)肠杆菌科的患者的一线治疗药物,包括儿科患者。我们旨在实施抗生素管理计划(ASP)以改善碳青霉烯类药物的使用。
我们在波尔多儿童医院实施了一项 ASP,在干预前后(修订抗生素治疗方案,半天的教育会议并反馈第一研究期的结果)进行了 6 个月的处方实践审核。分析了碳青霉烯类药物的处方数量,并使用了两个标准来评估碳青霉烯类药物处方的适应证一致性和重新评估的一致性。使用逻辑回归来评估两个时期的碳青霉烯类药物处方的总体依从性,调整了 ESBL 携带情况。
共纳入 57 例患者,其中干预前有 37 例碳青霉烯类药物处方,干预后有 23 例。碳青霉烯类药物的总消耗量从每 100 例入院 0.54 次降至 0.32 次(p=0.06)。在研究期间,适应证的一致性(46-87%,p=0.004)和重新评估的一致性(48-78%,p=0.04)均有所提高,并且与调整 ESBL 携带情况后的第二研究期显著相关。
我们的干预措施显著提高了碳青霉烯类药物适应证和处方重新评估的适应证的一致性。